CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions
CinCor Pharma announced positive results from its Phase 2 BrigHtn trial, showcasing the efficacy of baxdrostat in addressing resistant hypertension. The trial demonstrated a significant 20.3 mmHg reduction in systolic blood pressure at the 2 mg dose, with a statistically significant placebo-adjusted decline of 11 mmHg (p < 0.0001). Results indicate a well-tolerated profile with no serious adverse events. The company aims to provide further insights in a conference call on November 8, 2022, regarding the trial outcomes and implications for hypertension treatment.
- 20.3 mmHg reduction in systolic blood pressure at 2 mg dose, with a placebo-adjusted decline of 11 mmHg (p < 0.0001).
- No serious adverse events reported across all dose cohorts.
- Approximately 46% of participants in the 2 mg group achieved blood pressure control (SBP < 130 mmHg).
- None.
Aldosterone and renin biomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol
20.3 mmHg reduction in systolic blood pressure, or 11 mmHg (p-value < 0.0001) placebo-adjusted decline at the 2 mg dose
Well-tolerated profile and differentiated mechanism of action supports combination approaches
Conference call and live webcast Tuesday November 8th, 2022 at 7 AM Eastern Time
WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) announced the presentation today of Phase 2 data from its BrigHtn trial as part of the late-breaking science session at the 2022 American Heart Association (AHA) Scientific Sessions. Baxdrostat is a highly selective, once daily oral small molecule inhibitor of aldosterone synthase.
“We were honored to present our Phase 2 BrigHtn data as part of a late-breaking session focused on new treatments for the increasingly recognized unmet needs in resistant hypertension at this year’s AHA conference,” said Mason Freeman, M.D, Chief Medical Officer at CinCor. “Baxdrostat significantly decreases aldosterone in plasma and urine, while increasing plasma renin as a physiological compensatory change. These changes in aldosterone and renin following treatment with baxdrostat reflect less salt exposure to the kidney and reduced blood pressure over time. And, unlike earlier generations of aldosterone synthase inhibitors, serum cortisol levels were not reduced, once again confirming the highly selective mechanism of baxdrostat. Collectively these findings demonstrate how baxdrostat uniquely helps address a known cause of elevated blood pressure, potentially offering a much needed treatment option for patients with tough to control hypertension.”
BrigHtn Trial Highlights
Aldosterone and renin activity reinforce the biological mechanism of baxdrostat
- Dose-dependent reduction in both plasma and urine aldosterone support inhibition of aldosterone synthase and the mechanism of action of baxdrostat
- Urine aldosterone levels 24-hours post-treatment quantitatively measure total body aldosterone production with less variation than plasma to provide direct evidence of baxdrostat’s aldosterone lowering capabilities
- Dose-dependent changes in renin activity support physiological salt response
- No meaningful impact on cortisol confirms baxdrostat is highly selective for aldosterone synthase
Clinically meaningful and dose-dependent reduction in blood pressure with baxdrostat
- BrigHtn successfully met its primary endpoint, demonstrating a statistically significant change from baseline in mean seated systolic blood pressure (SBP) versus placebo:
- Dose-dependent reductions in SBP of −20.3 mmHg (2-mg), −17.5 mmHg (1-mg), and −12.1 mmHg (0.5-mg)
- Statistically significant placebo-adjusted decreases of −11.0 (2-mg, P = 0.0001) and −8.1 (1-mg, P = 0.003)
- Secondary endpoint results included baxdrostat significantly lowering diastolic blood pressure (DBP) by 5.2 mmHg in the 2mg dose arm, and approximately
46% of patients in the 2 mg dose arm achieving blood pressure control (SBP less than 130mmHg) - Patient demographics and baseline characteristics were diverse and well-balanced across treatment arms
Clinical safety and tolerability of baxdrostat support a well-tolerated profile
- No drug related serious adverse events (SAEs) observed or major safety concerns were reported across all three dose cohorts tested after 12 weeks of treatment
- Transient and manageable adverse events of special interest included hypotension, hyponatremia, or elevated potassium levels
- Low discontinuation rate of less than
1% (2 patients) due to transient treatment-related adverse events; all patients completed the study on drug - Well-tolerated profile and differentiated mechanism of action supports combination approaches
The BrigHtn trial was a Phase 2 randomized, double-blind, placebo-controlled dose-ranging clinical trial designed to assess the safety and efficacy of baxdrostat in subjects who have not achieved their target blood pressure despite receiving three or more antihypertensive agents at their maximally tolerated doses, one of which must be a diuretic. The trial evaluated three active doses of baxdrostat (0.5 mg, 1.0 mg, and 2.0 mg) compared to placebo control in 275 patients randomized across all four dosing cohorts, with 248 patients completing. The primary endpoint of BrigHtn was the change in mean seated SBP from randomization to trial end after 12 weeks of treatment.
Conference Call and Webcast Information
CinCor management will hold a conference call and webcast Tuesday November 8th 2022 at 7 AM Eastern Time to provide an update on additional results from the Phase 2 BrigHtn trial presented at AHA 2022. The dial-in number for the conference call is 877-407-9039 (U.S./Canada) or 201-689-8470 (international). The conference ID for all callers is 13734379. The live webcast and replay may be accessed by visiting the CinCor website at https://www.cincor.com/events-presentations. The replay will be available for 30 days following the call.
About CinCor
CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, baxdrostat (CIN-107), a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.
About Baxdrostat (CIN-107)
Baxdrostat is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for patient populations with significant unmet medical needs, including treatment-resistant hypertension and primary aldosteronism. Hypertension, which is defined by the American College of Cardiology and the American Heart Association as resting blood pressure above 130/80 mm Hg, is generally acknowledged to be one of the most common preventable risk factors for premature death worldwide. Though often asymptomatic, hypertension significantly increases the risk of heart disease, stroke, and kidney disease, amongst other diseases. It is estimated that as much as
Forward-Looking Statements
This press release contains certain forward-looking statements, including, but not limited to, statements related to CinCor’s business in general; the therapeutic potential of baxdrostat (CIN-107), including its potential to be an effective treatment for patients with treatment-resistant hypertension, uncontrolled hypertension and CKD, and the ability of baxdrostat to address multiple unmet needs in patients; the potential of baxdrostat to emerge as a new mechanism of action in the hypertension treatment paradigm; and other statements that are not historical facts. Because such statements are subject to risks and uncertainties, actual results may differ from those expressed or implied by such forward-looking statements. Words such as “anticipates,” “believes,” “expected,” “intends,” “plan,” “may”, “will,” “project”, “estimate”, “continue,” “advance” and “future” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on CinCor’s current plans, objectives, estimates, expectations and intentions, involve assumptions that may never materialize or may prove to be incorrect and inherently involve significant risks and uncertainties, including factors beyond CinCor’s control, that could cause actual results, performance, or achievement to differ materially and adversely from those anticipated or implied in the statements, including, without limitation, CinCor has incurred significant operating losses since its inception; CinCor has a limited operating history and no history of commercializing products; CinCor will require substantial additional funding to finance its operations; CinCor’s business is entirely dependent at this time on the success of one drug, baxdrostat; initial, interim, “top-line” and preliminary data from clinical trials announced or published from time to time may change; CinCor may not be successful in its efforts to expand its pipeline beyond baxdrostat; success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials; enrollment and retention of patients in clinical trials could be delayed; CinCor relies and will rely on third parties to conduct, supervise and monitor existing clinical trials and potential future clinical trials; developments from the company’s competitors and the marketplace for the company’s products; and CinCor’s business, operations and clinical development timelines and plans may be adversely affected by the evolving and ongoing COVID-19 pandemic, geopolitical events, including the ongoing military conflict between Russia and Ukraine and related sanctions against Russia, and macroeconomic conditions, including rising inflation and uncertain credit and financial markets, and matters related thereto; and other risks and uncertainties affecting the company, including those described under the caption “Risk Factors” and elsewhere in CinCor’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC) on March 22, 2022, CinCor’s Quarterly Report on Form 10-Q for the three months ended September 30, 2022 filed with the SEC on November 3, 2022, and other filings and reports that CinCor may file from time to time with the SEC. Other risks and uncertainties of which CinCor is not currently aware may also affect the company’s forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. CinCor undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
| Contacts: | Investors: |
| Michael W. Kalb | Bob Yedid |
| CinCor Pharma, Inc. | LifeSci Advisors |
| EVP and CFO | ir@CinCor.com |
FAQ
What were the results of the Phase 2 BrigHtn trial for CINC?
When will CinCor discuss the BrigHtn trial results?
What is baxdrostat being developed for by CinCor?
How was the safety profile of baxdrostat in the BrigHtn trial?
What percentage of patients achieved blood pressure control in the trial?
